Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-01-07
1998-04-28
Weddington, Kevin E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514909, A61K 3144
Patent
active
057444773
ABSTRACT:
The present invention is directed to an improvement in a method of weight and/or body-fat reduction comprising a (preferably moderate) reduction in the caloric intake of a subject in need of such treatment in combination with administration to said subject of a prolactin inhibitor. Additionally, the present invention is directed to an improvement in a method for altering and/or resetting prolactin profiles (and thereby controlling one or more metabolic disorders such as obesity, excessive body fat, hyperlipidemia, hyperlipoproteinemia, hyperglycemia, hypercholesterolemia, hyperinsulinemia, insulin resistance, glucose intolerance, and Type II diabetes) comprising administration to a subject in need of such treatment of a prolactin inhibitor at a predetermined time or times during a 24-hour period in combination with a (preferably moderate) reduction of the caloric intake of said subject.
REFERENCES:
patent: 4219555 (1980-08-01), Rucman
patent: 4239763 (1980-12-01), Milavec
patent: 4659715 (1987-04-01), Meier
patent: 4749709 (1988-06-01), Meier
patent: 4783469 (1988-11-01), Meier
patent: 5006526 (1991-04-01), Meier
patent: 5344832 (1994-09-01), Cincotta et al.
patent: 5585347 (1996-12-01), Meier et al.
Barnett et al., Postgraduate Med. J. 56:11-14, 1980.
Bartness et al., J. Exp. Zoology 244:437-454, 1987.
Berle, Acta endocr. Suppl. 173, Abstract No. 104, 1973.
Burns, et al., Rev. Chronopharmacology 5:57-60, 1988.
Chemical Abstracts, vol. 109, No. 9, 66888w, Aug. 29, 1988.
Cincotta et al.,Amer. J. of Physiol. 285-93, Feb. 1993.
Cincotta et al., Life Sciences 45:2247-2254, 1989.
Cincotta et al., Ann Nutr Metab 33:305-14, 1989.
Cincotta et al., Horm. Metabol. Res. 21:64-68, 1989.
Cincotta et al., J. Endocrinology 120:385-391, 1989.
Cincotta et al., Experientia 43:416-417, 1987.
Cincotta et al., J. Endocr. 106:177-181, 1985.
Cincotta et al., J. Endocr. 106:173-176, 1985.
Cincotta et al., J. Endocr. 103:141-146, 1984.
Eisemann et al., J. of Animal Sci. 59(1)95-104, 1984.
Eisemann et al., J. of Animal Sci. 59(1)86-94, 1984.
Gnudi et al., Acta Diabetologica Latina 14:119-128, 1977.
Horseman et al., J. Endocr. 82:367-372, 1979.
Horseman et al., General and Comparative Endocrinology 38:269-274, 1979.
Joseph et al., J. Exp. Zool. 178(1):59-62, 1971.
Landgraf et al., Proc. German Med. Soc. 82nd Convention, Part II, Apr. 25-29, 1976.
Lee et al., J. of Exp. Zool. 166(3):307-316, 1969.
Meier et al., Nature 271:469-471, 1978.
Meier, et al., Experientia 48:248-253, 1992.
Meier, Amer. Zoology, 15:905-916, 1975.
Meier, Amer. Scientist 61(2)184-187, 1973.
Meier, Gen. & Comp. Endocrin. Supp. 2:55-62, 1969.
Meier et al.,Gen. & Comp. Endocrin. 8(1):110-114, 1967.
Meier et al.,Compar. Endocrin. 141-44, 1978.
Meier et al., Amer. J. of Physiology 232(2):E193-E196, 1977.
Meier et al., Amer. Zool. 16:649-659, 1976.
Southern et al., J. Anim. Sci. 68:931-936, 1990.
Spieler et al., Gen. & Comparative Endocrinology 29:156-160, 1976.
Spieler et al., Life Sciences 22:255-258, 1977.
Thomas et al., Semaine des Hopitaux de Paris 53(34-35):1857-1862, 1977.
Wheeland, et al., Comp. Biochem. Physiol. vol. 53B; 379-385, 1976.
Wilson et al., Chronobiology Int'l 6(2):113-121, 1989.3:189-195, 1989.
Meier et al., Science 173: 1240-42, 1971.
Meier et al., Gen. & Comp. Endocrin. 17: 311-8, 1971.
Martin et al., Neuroendocrinology 52: 9-14, 1990.
Martin et al., The Condor 75: 369-374, 1973.
Cassar, J. et al. "Bromocriptine Treatment of Acromegaly," Metabolism 26: 539-546 (1977).
Dolocek, R. et al. "Bromocriptine and glucose tolerance in acromegalics," Pharmatherapeutica 3: 100-106 (1982).
Eskildsen, P.C. et al. "Long-Term Treatment of Acromegaly with Bromocriptine," Acta Endocr. 87: 687-700 (1978).
Steinbeck, K. and J.R. Turtle, "Treatment of Acromegalywith Bromocryptine," Aust. N.Z. J. Med.9: 217-224 (1979).
Wass, J.A.H. et al. "An Assessment of Glucose Intolerance In Acromegaly and Its Response to Medical Treatment," Clin. Endocr. 12: 53-59 (1980).
Cincotta Anthony H.
Meier Albert H.
Ergo Research Corporation
The Board of Supervisors of Louisiana State University and Agric
Weddington Kevin E.
LandOfFree
Method for treatment of obesity using prolactin modulators and d does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treatment of obesity using prolactin modulators and d, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treatment of obesity using prolactin modulators and d will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1532184